Marketing strategies of GMP syndrome（GMP综合症的营销对策）.docx

《Marketing strategies of GMP syndrome（GMP综合症的营销对策）.docx》由会员分享，可在线阅读，更多相关《Marketing strategies of GMP syndrome（GMP综合症的营销对策）.docx（13页珍藏版）》请在课桌文档上搜索。

1、MarketingstrategiesofGMPsyndrome（GMP综合症的营销对策）MarketingstrategiesofGMBsyndrome（GMP综合症的营销对策）AccordingtotherelevantdepartmentsofSFDAstatistics,beforeJuly1st,throughtheGMPcertificationofpharmaceuticalenterprisesinabout3100,accountingfor60%ofthecountry.Thereare2000enterprises,nearly900workshopswereforced

2、tostopproduction.EnterprisesthathavepassedGMPaccountfor90%ofthedomesticpharmaceuticalmarket,andthedrugscoveral1thecommonlyusedclinicalproducts,whichcancompletelymeetthemarketdemand.Thereisasayingintheindustry:butGMPGMPisdead,too!Infact,GMPisnotanadministrativetypeofdeathlaw;theimplementationofGMPisa

3、neconomictypeofdeath.ButtherewaslittlenewsornewsthataroundanumberofsmallandmediumenterprisestoabandonGMPcertificationinJuly1staftertheclimaxcontinued,issaidbyGMBtoreducetherepeatedlowleveloftheoriginalbuildingislost!However,smallandmedium-sizedpharmaceuticalcompanieshavepassedthenationalGMPcertifica

4、tion,butitisdifficulttoberecognizedbythemarket,generallysufferingfromGMPsyndrome,thefollowingauthoronthisissue,talkabouttheirownthinkingandcountermeasures.Oneofthesymptoms,operatingcostssubstantialIyimproved1,thecostofimprovingtheclinicalperformance(1)thecostofpassingGMPisprohibitive11isunderstoodth

5、atGMPhasmorethan80certificationrules,includingmorethan200inspectioniternsetc.druglabelsandinstructionsforuse,ordrug,involvesmanyaspectsofsoftwareandhardware,managementcontent,theimplementationofGMPisacomplicatedandhugesystemengineering.Accordingtopublicinformation,on1ythetransformationofafactory,ent

6、erprisesspendlessthantheamountofmillionsoffunds,morethantensofmillionsofdegrees.AccordingtothesurveyresearchcenterChinasocialeconomicsurveyinconjunctionWithrelevantassociationsChinapharmaceuticalenterprisecompetitivenessresearchgroupinSichuan,anareaofatotalof21pharmaceuticalcompanies,fixedassetsof1.

7、8million,totalinvestmentandthetransformationofGMP5companiesis220millionyuan.Theannualoutputvalueofanenterpriseisonly10millionyuan,thescientificresearchstrengthisveryweak,only30varietiesandtheproductionofgenericdrugstomaintain,financing50millionyuanthroughtheGMPcertification,howtomaketheequipmentidle

8、,whatproductionvarieties,hasbecometheproblem：seeingloanmaturity,whilethesalesamountisstagnating,lettheenterpriseresponsibleforpeoplescorchedbytheflames.Xi,anpharmaceutical1imited1iabi1itycompanyspent35mi11ionyuanrenovationoftraditionalChinesemedicinepreparationworkshopandpassedtheGMPcertification,th

9、eannualproductioncapacityof50millionyuanincreasedtonearlybillionyuan,butbecauseoperatingcostsincreasedby20times,thepressureascanbeimagined.(2)theoperationcosthasbeengreatlyimprovedAIlcompanieshavesomeGMPafterincreasedoperationalcosts,theauthorheardenterprisemadeinthegovernmentheldameetingtosolvereal

10、businessproblems:thegovernmentwillallowustomovebacktothenonGMPworkshopproductionoftheoriginaljoke.Thehighoperatingcostsaremanifestedinthefollowingaspects:#61548:firstofall,theproductioncostshavebeengreatlyimproved:theutilitieshavebeensubstantialIyimproved;forexample,apharmaceuticalcompanyinGuangxiha

11、son1yoneelectricitybi11permonth,anincreaseof10thousandyuanmorethanthatoftheoriginalnonGMPworkshop.GuangdongJiangmensomepharmaceuticalcompaniesthroughtheGMPcertification,productioncoststhantheoriginalincreaseofmorethan30%.Theincreaseinproductioncostswillmakesomeoftheprofitmarginsthatoriginallyre1icdo

12、nsalesvolumes.?managementcostsincreased:strictlyinaccordancewiththeGMPstandardmanagementoperations,makingmanagementcostssoared,butalsoalotofenterprisesoverwhelmed.?lowproductionefficiency:thecausesofthe1owefficiencyofthefollowingmainreasons:theselectionofequipment,equipmentinstallation,nowrongworker

13、shaven,tmasteredthetechnicalparametersoftheequipment,withoutlearningcurve.?newplant,equipmentoperationisnotskilled,theproductsproducedhighrateoffailure.2,tosolvetheprescriptionPrescriptionone,large-scaleproduction,improveefficiencyRapidincreaseofproductionworkersonequipmentproficiency,stopproduction

14、byagroupofcompetentgettersintheshortterm,tograsptheoperationtechnology,shortenthelearningcurveandreducethecostoflearningcurve.Onlyinthiswaycantherateofdefectiveproductsbereducedassoonaspossible,andtheadvantagesofthenewequipmentwi11bebroughtintoplay,Improvetheproductionefficiency,inthefiercemarketcom

15、petitionenvironment,largescaleproduction,andstrictlycontroleverylinkcosts,isundoubtedlytheonlypropercoursetotakeenterprisestoWinthecompetitiveadvantageoflowcost.Withthecostofrawmaterialsandvariouscostsdown,thetotalcostisautomaticallyreduced.Thesalespriceis10yuanthesameproduct,ifthecostfromtheorigina

16、l5yuandownto3yuannow,sotheenterprisecannotdevelopnewconsumers,occupynewmarket,butalsofromtheexistingmarketsharetowinmorethantheoriginalsalesprofit.Prescriptiontwo,assoonaspossibletopreventproductionoftechnicalpersonneltotacklekeyissues,shortentheproductionoflearningcurvetimeIntheprocessofproducingap

17、roductmultipletimes,itisobservedthattheamountofresourcesneededtoproduceaunitofproductioncontinuouslydecreasesastheamountofaccumulatedoutputincreases.Thediminishingeffectofinputfactorsandrelatedcostsisthelearningeffect.Withtheincreaseoftheproductionquantityofproductstogetaproductneededtimeandmaterial

18、consumptiondecreasedduetoaseriesoffactors,thesefactorsinclude:reducingtheworkerstowork,improvetheproficiencyoftheworkingmethodsandprocessimprovement,wasteandrepeatedwork.Thelearningcurve(empiricalcurve)requiresskilledindustrialworkers.TheproductionprocessoperationandautomobiIedriving,workersneedlove

19、,sensitivetorepeatedexplorationtomachines,ski1led,andmustbeintheactualoperationtoberipeinstudents,andgraspthecharacteristicsofthemachine.ProficiencyinthemachineisnotaShOrt-termlearningcando,isaneedfortimeexperienceprocess.Manypharmaceuticalcompanieson1ypayattentiontothehardwareinvestment,donotpayatt

20、entiontothetrainingofskilledindustrialworkers,theresultscanimprovetheefficiencyandeffectivenessofthenewequipment,newmachines,butnottheadvantage,lowefficiency,oftenwrong,thisisnotthemachinefault,faultmanagementtraining.Irespectfullysuggest,theGMPpharmaceuticalcompanies,aresearchgroup,quicklyestablish

21、eddayandnight,tofindoutthemachineworkingconditions,Iechnicalparametersandoperationrules;masterthekeycontrolpointsofeachprocess,assoonaspossibletoshortenthelearningcurveforthetime,reducetheproductionprocesstimeandrawmaterialconsumptioncost.Prescriptionthree:lookingforfast,highvolume,sharpmarketingmod

22、elssuchasterminalintercept,conferencemarketing,urbanandruralpromotion.1.ookingforagents,etc.Toreducetheamountofmoneyneededforsale.Symptomsoftwo:idlecapacity(1)clinicalmanifestation;InShanghai,GuangdongandotherplaceshavepassedGMPcertification,theoutputvalueofenterprisesevenaccountedformorethan90%ofth

23、ecity,Stotaldrugproduction.ChinaPharmaceuticalEnterpriseManagementAssociationexecutivepresidentYuMingdethink,afterGMPcertification,China,spharmaceuticalindustryovercapacityoveral1situationwillaggravate.Itisunderstoodthatalmostal1pharmaceuticalenterprisesintheGMPtransformation,havevaryingdegreesofexp

24、ansion.Manyenterpriseshavetheideathatitisdifficulttoborrowfunds,butalsotobuildtheworkshop,butalsotobuyequipment,whynotbuildmorethanoneproductionline?ThisidealeadstoasubstantialincreaseintheproductioncapacityofenterprisesaftertheGMPtransformation.SuchasMaoxianggroup,sacquisitionofMcihePharmaceuticalC

25、o.1.td.afteraGMPproject,atotalinvestmentof95million895thousandyuan,aftertheformationofextractionof500tons,100mi11ioncapsules,500milliontablets,pills,oralliquidproductioncapacityof100mi11ion.CentralPharmaceuticaltransformationofTianjinlasted3yearsunti1completion,thetotalinvestmentof60mi11ionyuan,thep

26、roductioncapacityincreasesgreatlythaninthepast.StatisticaldatafromtheBcijingconpartpharmaceuticaleconomicandtechnologyresearchcenter,throughtheGMPcertificationofenterprises,about65%oftheproduction1ineputenough;morethan50%businessownersinnewvarietiesaround.(2)diagnosisandtreatmentprescription:OEMgene

27、rationprocessing,digestion,idlecapacity.ThedirectoroftheSFDwhiteboardsaidthattheproductionofdrugsbyentrustmentwascommoninforeigncountriesandthatsocialresourcescou1dberationallyused.TherevisedDrugAdministration1.awofChinaalsomadeaclearprovisionforthis.Onthisquestion,Shou1dalsobeinlinewithChina,snatio

28、nalconditions,andgraduallystepclosertointernationalpractice.tpresent,wemustimplementtheissuedlawsandregulationstoensurethesmoothproductionofpharmaceuticalentrustedproduction.Prescription1:crosscombinationOEM:Enterprisescanactivelyseektocooperatewithsomelargepharmaceuticalenterprises,andbecometheirpr

29、oductionworkshop,andearnproductionprofits.Becauseofnonewproductfollow-up,SMEsfacedifficultiesinstartingGMP.CanNorthSouthcooperationandNorthSouthenterprisestohelpenterprisescommissionedprocessing,SouthNorthenterprisestohelpenterprisesOEM,orsomethingcooperation,sowewillgreatlyreducethecostoftransporta

30、tion,especiallyforthesaleofsmallradiusofheavywater,whichissuitabletogranules.Prescriptiontwo:verticaljointOEM:solvingtheOEMimpulseofcirculationenterprisesInfact,drugentrustedprocessinghasbeeninexistenceforalongtime,andpharmaceuticaldistributionenterprisesorpharmaceuticalmarketingpersonnelhaveentrust

31、edthemanufactureofpharmaceuticalcompaniestoaccountforthelargestproportionofentrustedprocessing.MainlyengagedinpharmaceuticalbusinessinShenzhenKangFuIndustrialCompanyChairmanTangWeimingtoldreporters:inthepastsomeofthedrugsbyprocessingmoresubtle,suchastheSouthernChinacoastalareahasbeeninasneakywayforH

32、ongkongpharmaceuticalproducts,donotgothroughanyformalities.WiththeStandardizationofthepharmaceuticalindustryandtheincreaseofidlerateofpharmaceuticalequipmentafterGMP,thepharmaceuticalprocessingbusinesswillbemoreheated,andtheupwardenthusiasmofthecirculationcompanieswillcontinuetorise.Iknowapharmaceut

33、icaldealerinSichuan,expressedhisdesiretodevelopdrugs,sothatmanufacturersOEMOEM.Themedicinecirculationenterprisedynamicofdrugsalesmarketandfuturetrendsareabletobettergraspandknowwhatproductscanbringprofitfortheenterprise,butoftentofindsuchproductsandspendenormousenergy,butalsototheexclusivemanufactur

34、erZhunzixclassofdrugsetc.Farmar,improveproductfactoryprice,pressagentprofit,sothatagentsindifficultposition.saresult,theyareeagertodevelopproductswiththeirownintelIectualpropertyrights.ButbecausetheyhavenoGMPworkshop,theycannotproject,whichbringsopportunitiesforpharmaceuticalenterprises.Itisentirely

35、possibletoworkwiththeseenterprisestodevelopproductsfortheirexclusiveproduction.Prescriptionthree:OEMforforeignpharmaceuticalcompaniesHere,specialattentiontodomesticpharmaceuticalcompaniestopayattentiontoandforeignpharmaceuticalgiantmultinationalcorporation,foritsOEM.CheaplaborChineseandrelativelyche

36、approductioncosts,candodrugsforforeignpharmaceuticalcompaniesinChinaoutsourcingproduction,buttheproductionprocesstheoriginalChinesepharmaceuticalbackwardandunstableproductqualitygreat1yhindersthepatternofahMPcertificationforaccountedforforeignpharmaceuticalcompaniesinChineseproductionoutsourcingclea

37、ningobstacle.JiangsuandZhejiangprovincesofthepharmaceuticalcompanieshavebeguntotrythis,suchastheUnitedSlatesZhejiangHisunMerck,Suzhou1.idaforWyethpharmaceuticalprocessingandsoon.Globalwel1-knownpharmaceuticalenterpriseshaveal1enteredChina,Ibe1ievethisshouldbealargermarket.October13,2004,wasthefirstm

38、ajorpharmaceuticalcompaniesoftheFarEastShanghaiXinyipharmaceuticalsofficiallyannounced,thefactoryhasbeenestablishedthefirstFDAwiththeUnitedStatesandtheEuropeanUnionCGMPstandardsolidpreparationproductionbaseofourcountrystate-ownedpharmaceuticalenterprises,thetotalinvestmentwillreach200millionyuan.The

39、productionbasedesignannualproductionof5bi11iongrain,inadditiontotheproductionofXinyiitselflistedEuropeanmarketdrugs,butalso1istcdEuropeanmarketofpharmaceuticalOEMproduction.Prescriptionfour:rapidimitationofexpiredtraditionalChinesemedicineprotectionvarieties,andpatentexpiredvarieties,orrapiddevelopm

40、entofhealthfood,digestionandproductioncapacityRDconstraints,genericdrugsarestilldominant.Chinaspharmaceuticalmarkethasbeendominatedbygenericdrugsforalongtime.ASaresultofinstitutionalreasons,long-termRDfundsareseriouslyinadequateanddonotpayattentiontoRf),sothatenterprisesdonothavenewproducts,thereisn

41、osustainabledevelopmentcapacity.PharmaceuticalcompaniesareexemptfromGMPcertification,andbecauseofthelargeamountofmoneybeingdepositedonGMPprojects,andmos11yloans,thereisnomoremoneyforresearchanddevelopment.Butcapacityisreallymagnified,sogenericsremaindominant,foralongtimetocome.1.owlevelimitationandp

42、ricewarwillstillbethemainstreamphenomenoninthemarket.About60%ofSMEsinvaryingdegreestowithstandnewresearchanddevelopment,bankloans,marketingchannelconstruction,lackoffundsenormouspressure.Thismakestheenterprisesurgentlyneedtoseebenefitsintheshortestpossibletime,suggesttotakesometechnicalcontentisshor

43、t,flat,fastlowprojecttotrytoimitatetheprotectionoftraditionalChinesemedicineaspressingdanger,goodmarketprospectsduetovarieties,varietiesofpatentexpiration.Anotherideaistodeveloporbuyhealthfoodassoonaspossible,tostarthealthfoodproduction,healthfooddevelopmentcycleisshort,lessinvestment,itcanberegarde

44、dasagoodrecipefordigestivecapacity.Threeofthesymptoms,theproductproductioncostsincreased,pricesincreased,competitivenessdeclined1,symptoms:Smailscale,poorbenefits,compelitivedec1ineThepresentsituationofourcountry,Sdrugisaccountedfor70%ofthemarketforgenericdrugs,profitsaccountedforonly30%;andthemarke

45、tshareof30%ofthedrug,itsprofitisashighas70%,throughtheGMPcertification,drugpriceswillbehigher,becausedepreciationthroughGMPisfarlessthanitsprofits.Thereisnoprofitbecauseofgenericdrugs,genericdrugsarelessprofitable,cannotcompensatefordepreciationandinterestonloans.Fromthesmal1andmedium-sizedenterpris

46、esprofitlevel,theoriginalmarketcompetitionhasbeenveryintense,andhasintensified,somerelyonpricewarandwinthetemporaryinterestsofthesmal1andmedium-sizedpharmaceuticalenterprises,afterGMPcertification,withtheincreaseofrawmaterialcostsandoverallcosts,increasedoperatingcosts,butalsomakesitsownthepriceadva

47、ntageofthemomentcometonothing.Inmarketcompetition,facingthehighcost,smal1andmedium-sizedpharmaceuticalenterpriseswillbeforcedbyreducingtheirprofitratiotogainnewadvantages,inordertousethepriceofweaponsandcompetitorsrushtoahigherlevel.Inthisway,moreandmoresmallandmedium-sizedpharmaceuticalenterprisesa

48、reenteringunprofitablestatus.Thecompetitivenessofsmallandmedium-sizedpharmaceuticalenterpriseshasbeenfurtherweakened.2,tosolvetheprescriptionTheauthorputsforwardthefollowingcountermeasures:Prescription1:abandonthefollowingzeroprofitproductproduction,selectpotentialandprofitableproducts,focusonlarge-

49、scale!Notafraidofsomeproductionlineshutdown.#61548specializesinproducingindividualvarietiesdirectlyforseverallargepharmaceuticallogisticscompaniesThisisdifferentfromOEM,buttheirproductsspecificallyforseverallargelogisticscompanytodo,inordertoreducetheintermediatelinkagent,theformationofdirectsupplypriceadvantage,increasethelargelogisticscompany,spurchasequantityandpurchasefrequency,reducethesalesprocessmanagementfees,andquicklyexpandthemarket.Ifyourmarketingeffortsandmarketingnetworkcoveragetotheseplaces,andthereisthebestnetworkoflargepharmaceuticallogisticsenterprisessuch